Spots Global Cancer Trial Database for Study of TG-1801 in Subjects With B-Cell Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of TG-1801 in Subjects With B-Cell Lymphoma
Official Title: A Phase 1 First-in-Human Study of Bispecific Antibody TG-1801 in Subjects With B-Cell Lymphoma
Study ID: NCT03804996
Conditions
Study Description
Brief Summary: Phase 1 first in human Study to Assess the Bispecific Antibody TG-1801 in Subjects with B-Cell Lymphoma
Detailed Description: This is an open-label, multi-center, accelerated titration design study. Planned enrollment includes 1 subject at low dose levels. Subjects will receive weekly infusions of TG-1801 in a 4 week-cycles.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
TG Therapeutics Investigational Trial Site, Heidelberg, Victoria, Australia
TG Therapeutics Investigational Trial Site, Melbourne, Victoria, Australia
TG Therapeutics Investigational Trial Site, Nedlands, Western Australia, Australia
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
